Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
YENEO-001 by NantBioScience for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
YENEO-001 is under clinical development by NantBioScience and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
Data Insights
YENEO-001 by NantBioScience for Non-Small Cell Lung Cancer: Likelihood of Approval
YENEO-001 is under clinical development by NantBioScience and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...